Therapeutic implications of central and peripheral neurologic mechanisms in migraine

Neurology

Volumn 61, Issue 8 SUPPL., 2003, Pages

  Waeber, Christian ^a,b   Moskowitz, Michael A ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; 1 [2 [4 (4 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N METHYLISOCHROMAN 6 CARBOXAMIDE; 5 (4 FLUOROBENZAMIDO) 3 (1 METHYL 4 PIPERIDINYL) 1H INDOLE FUMARATE; ALNIDITAN; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ANTIMIGRAINE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL; CALCIUM CHANNEL BLOCKING AGENT; CHLORPROMAZINE; CYPROHEPTADINE; DIHYDROERGOTAMINE; ERGOTAMINE TARTRATE; FROVATRIPTAN; GABAPENTIN; GLYCERYL TRINITRATE; METHYSERGIDE; N(G) NITROARGININE METHYL ESTER; NARATRIPTAN; PNU 142633; PROPRANOLOL DERIVATIVE; PURINE P2X RECEPTOR; PURINERGIC RECEPTOR BLOCKING AGENT; RIZATRIPTAN; SEROTONIN; SEROTONIN 1B AGONIST; SEROTONIN 1D AGONIST; SUMATRIPTAN; TRAZODONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZOLMITRIPTAN;

CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG INFUSION; DRUG SAFETY; ENVIRONMENTAL FACTOR; GENETICS; HUMAN; MIGRAINE; MOLECULAR DYNAMICS; NONHUMAN; PATHOPHYSIOLOGY; PERIPHERAL NERVE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT;

EID: 0345659224     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.61.8_suppl_4.s9     Document Type: Review

References (160)

1. Garcia-Albea E. Neurology in the medical papyruses of the pharaohs. Rev Neurol 1999;28:430-433.
2. Karenberg A, Leitz C. Headache in magical and medical papyri of ancient Egypt. Cephalalgia 2001;21:911-916.
3. Rapoport A, Edmeads J. Migraine: the evolution of our knowledge. Arch Neurol 2000;57:1221-1223.
4. Willis T. The London practice of physick. London: Thos Basset & Wm Crooke, 1685:380.
5. Willis T. The anatomy of the brain and nerves. In: Feindel W, ed. Birmingham: The classics of neurology and neurosurgery library. 1983:90.
6. Ray BS, Wolff HG. Experimental studies on headache: pain-sensitive structures of the head and their significance in headache. Arch Surg 1940;41:813-856.
7. Koehler PJ, Isler H. The early use of ergotamine in migraine. Edward Woakes' report of 1868, its theoretical and practical background and its international reception. Cephalalgia 2002;22:686-691.
8. 1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia 2002;22:633-658.
9. Reuter U, Sanchez del Rio M, Moskowitz MA. Experimental models of migraine. Funct Neurol 2000;15(suppl 3):9-18.
10. Tfelt-Hansen P, Saxena PR, Dahlof C, et al., Ergotamine in the acute treatment of migraine: a review and European consensus. Brain 2000;123:9-18.
11. Silberstein SD. The pharmacology of ergotamine and dihydroergotamine. Headache 1997;37(suppl 1):S15-25.
12. Graham JR, Wolff HG. Mechanism of migraine headache and action of ergotamine tartrate. Arch Neurol Psychiatr 1938;39:737-763.
13. Humphrey PPA, Feniuk W, Marriott AS, Tanner RNJ, Jackson MR, Tucker ML. Preclinical studies on the anti-migraine drug, sumatriptan. Eur Neurol 1991;31:282-290.
14. Hoyer D, Clarke DE, Fozard JR, et al. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol Rev 1994;46:157-203.
15. Kaube H, Hoskin KL, Goadsby PJ. Inhibition by sumatriptan of central trigeminal neurones only after blood-brain barrier disruption. Br J Pharmacol 1993;109:788-792.
16. 1B/1D agonists in a model of trigeminovascular nociception in cat. Exp Neurol 1998;150:45-51.
17. Ryan R, Geraud G, Goldstein J, Cady R, Keywood C. Clinical efficacy of frovatriptan: placebo-controlled studies. Headache 2002;42(suppl 2):S84-92.
18. Pauwels PJ, John GW. Present and future of 5-HT receptor agonists as antimigraine drugs. Clin Neuropharmacol 1999;22:123-136.
19. Young WB, Mannix L, Adelman JU, Shechter AL. Cardiac risk factors and the use of triptans: a survey study. Headache 2000;40:587-591.
20. 1-like agonists in the treatment of migraine. J Neurol 1991;238(suppl 1):S57-61.
21. Moskowitz MA. Neurogenic versus vascular mechanism of sumatriptan and ergot alkaloids in migraine. Trends Pharmacol Sci 1992;13:307-311.
22. 1B/1D receptors in the treatment of migraine. CNS Spectrums 1998;3:30-39.
23. 1F receptor agonists in human and bovine cerebral arteries: similarity with human coronary artery. Br J Pharmacol 2000;129:501-508.
24. Bouchelet I, Cohen Z, Case B, Seguela P, Hamel E. Differential expression of sumatriptan-sensitive 5-hydroxytryptamine receptors in human trigeminal ganglia and cerebral blood vessels. Mol Pharmacol 1996;50:219-223.
25. 1B receptors. Mol Pharmacol 1996;49:761-765.
26. 1D receptor agonist, on electrically induced dural plasma extravasation and capsaicin-evoked c-fos immunoreactivity within trigeminal nucleus caudalis. Neuropharmacology 1999;38:1043-1053.
27. 1F receptors modulate c-fos expression within rat trigeminal nucleus caudalis. Eur J Pharmacol 1999;369:271-277.
28. Diener HC, Tfelt-Hansen P, de Beukelaar F, et al. The efficacy and safety of sc alniditan vs. sc sumatriptan in the acute treatment of migraine: a randomized, double-blind, placebo-controlled trial. Cephalalgia 2001;21:672-679.
29. 1F receptor agonists inhibit neurogenic dural inflammation in guinea pigs. Neuroreport 1997;8:2237-2240.
30. 1F receptor agonist (SSOFRA) LY334370. Cephalalgia 1999;19:318.
31. Buzzi MG, Carter WB, Shimizu T, Heath H, III, Moskowitz MA. Dihydroergotamine and sumatriptan attenuate levels of CGRP in plasma in rat superior sagittal sinus during electrical stimulation of the trigeminal ganglion. Neuropharmacology 1991;30:1193-1200.
32. 1Dalpha serotonin receptor gene expression in trigeminal ganglia: implications for antimigraine drug development. Proc Natl Acad Sci USA 1994;91:3666-3669.
33. 1B/1D/1F receptors and glutamate in trigeminal ganglia in rats. Neuroreport 2001;12:1589-1591.
34. 1D receptor mRNA differential co-localization with peptide mRNA in the guinea pig trigeminal ganglion. Neuroreport 1998;9:641-645.
35. 1B/1D receptors and substance P in trigeminal ganglion neurons in rats. Eur J Neurosci 2001;13:2099-2104.
36. 1F receptor messenger RNA in rodent and primate brain. Neuropharmacology 1994;33:367-386.
37. 1F receptor agonist LY334370. Cephalalgia 1999;19:851-858.
38. 1D agonist, in patients with acute migraine. Cephalalgia 2001;21:727-732.
39. 1D agonists: potential new treatment for migraine without cardiovascular side effects. J Med Chem 1998;41:2180-2183.
40. The International 311C90 Long-term Study Group. The long-term tolerability and efficacy of oral zolmitriptan (Zomig, 311C90) in the acute treatment of migraine. An international study. Headache 1998;38:173-183.
41. Pascual J, Cabarrocas X. Within-patient early versus delayed treatment of migraine attacks with almotriptan: the sooner the better. Headache 2002;42:28-31.
42. Hu XH, Raskin NH, Cowan R, Markson LE, Berger ML. Treatment of migraine with rizatriptan: when to take the medication. Headache 2002;42:16-20.
43. Cady RK, Sheftell F, Lipton RB, et al. Effect of early intervention with sumatriptan on migraine pain: retrospective analyses of data from three clinical trials. Clin Ther 2000;22:1035-1048.
44. Halpern MT, Lipton RB, Cady RK, Kwong WJ, Marlo KO, Batenhorst AS. Costs and outcomes of early versus delayed migraine treatment with sumatriptan. Headache 2002;42:984-999.
45. Klapper JA, Rosjo O, Charlesworth B, Jergensen AP, Soisson T. Treatment of mild migraine with oral zolmitriptan 2.5 mg provides high pain-free response rates in patients with significant migraine-related disability. Neurology 2002;58:A416. Abstract.
46. Davidoff RA. Migraine, manifestations, pathogenesis, and management. 2nd ed. Oxford: Oxford University Press, 2002.
47. Strassman AM, Raymond SA, Burstein R. Sensitization of meningeal sensory neurons and the origin of headaches. Nature 1996;384:560-564.
48. Burstein R, Yamamura H, Malick A, Strassman AM. Chemical stimulation of the intracranial dura induces enhanced responses to facial stimulation in brain stem trigeminal neurons. J Neurophysiol 1998;79:964-982.
49. Burstein R. Deconstructing migraine headache into peripheral and central sensitization. Pain 2001;89:107-110.
50. Blau JN, Dexter SL. The site of pain origin during migraine attacks. Cephalalgia 1981;1:143-147.
51. Drummond PD. Scalp tenderness and sensitivity to pain in migraine and tension headache. Headache 1987;27:45-50.
52. 1B/1D agonist. Br J Pharmacol 1999;126:1478-1486.
53. Burstein R, Yarnitsky D, Goor-Aryeh I, Ransil BJ, Bajwa ZH. An association between migraine and cutaneous allodynia. Ann Neurol 2000;47:614-624.
54. Randic M, Jiang MC, Cerne R. Long-term potentiation and long-term depression of primary afferent neurotransmission in the rat spinal cord. J Neurosci 1993;13:5228-5241.
55. Yu XM, Askalan R, Keil GJ II, Salter MW. NMDA channel regulation by channel-associated protein tyrosine kinase Src. Science 1997;275:674-678.
56. Li P, Kerchner GA, Sala C, et al. AMPA receptor-PDZ interactions in facilitation of spinal sensory synapses. Nat Neurosci 1999;2:972-977.
57. Diaz A, Dickenson AH. Blockade of spinal N- and P-type, but not L-type, calcium channels inhibits the excitability of rat dorsal horn neurones produced by subcutaneous formalin inflammation. Pain 1997;69:93-100.
58. Gee NS, Brown JP, Dissanayake VU, Offord J, Thurlow R, Woodruff GN. The novel anticonvulsant drug, gabapentin (Neurontin), binds to the α2δ subunit of a calcium channel. J Biol Chem 1996;271:5768-5776.
59. Field MJ, Oles RJ, Lewis AS, McCleary S, Hughes J, Singh L. Gabapentin (neurontin) and S-(+)-3-isobutylgaba represent a novel class of selective antihyperalgesic agents. Br J Pharmacol 1997;121:1513-1522.
60. Di Trapani G, Mei D, Marra C, Mazza S, Capuano A. Gabapentin in the prophylaxis of migraine: a double-blind randomized placebo-controlled study. Clin Ther 2000;151:145-148.
61. Mathew NT, Rapoport A, Saper J, et al. Efficacy of gabapentin in migraine prophylaxis. Headache 2001;41:119-128.
62. Hu B, Chiang CY, Hu JW, Dostrovsky JO, Sessle BJ. P2X receptors in trigeminal subnucleus caudalis modulate central sensitization in trigeminal subnucleus oralis. J Neurophysiol 2002;88:1614-1624.
63. Woolf CJ, Salter MW. Neuronal plasticity: increasing the gain in pain. Science 2000;288:1765-1769.
64. Akopian AN, Souslova V, England S, et al. The tetrodotoxin-resistant sodium channel SNS has a specialized function in pain pathways. Nature Neurosci 1999;2:541-548.
65. Chen CC, Akopian AN, Sivilotti L, Colquhoun D, Burnstock G, Wood JN. A P2X purinoceptor expressed by a subset of sensory neurons. Nature 1995;377:428-431.
66. Cutrer FM, Waeber C, Moskowitz MA. Headache. In: Enna SJ, Coyle JT, eds. Pharmacological management of neurological and psychiatric disorders. New York: McGraw-Hill, 1998:525-568.
67. Wolff HG. The cerebral circulation. Arch Neurol Psychiatr 1929;22:686-699.
68. Olesen J, Iversen HK, Thomsen LL. Nitric oxide supersensitivity: a possible molecular mechanism of migraine pain. Neuroreport 1993;4:1027-1030.
69. Lassen LH, Ashina M, Christiansen I, et al. Nitric oxide synthase inhibition: a new principle in the treatment of migraine attacks. Cephalalgia 1998;18:27-32.
70. Trainor DC, Jones RC. Headaches in explosive magazine workers. Arch Environ Health 1966;12:231-234.
71. Shimomura T, Murakami F, Kotani K, Ikawa S, Kono S. Platelet nitric oxide metabolites in migraine. Cephalalgia 1999;19:218-222.
72. Stepien A, Chalimoniuk M, Stepien A, Chalimoniuk M. Level of nitric oxide-dependent cGMP in patients with migraine. Cephalalgia 1998;18:631-634.
73. Leone M, Attanasio A, Croci D, et al. The serotonergic agent m-chlorophenylpiperazine induces migraine attacks: a controlled study. Neurology 2000;55:136-139.
74. Fozard JR, Kalkman HO. 5-Hydroxytryptamine (5-HT) and the initiation of migraine: new perspectives. Naunyn Schmiedebergs Arch Pharmacol 1994;350:225-229.
75. Millan MJ. The induction of pain: an integrative review. Prog Neurobiol 1999;57:1-164.
76. Luo ZD, Cizkova D. The role of nitric oxide in nociception. Curr Rev Pain 2000;4:459-466.
77. Murrel W. Nitro-glycerin as a remedy for angina pectoris. Lancet 1879;1:80-81.
78. Read SJ, Manning P, McNeil CJ, Hunter AJ, Parsons AA. Effects of sumatriptan on nitric oxide and superoxide balance during glyceryl trinitrate infusion in the rat: implications for antimigraine mechanisms. Brain Res 1999;847:1-8.
79. Reuter U, Bolay H, Jansen-Olesen I, et al. Delayed inflammation in rat meninges: implications for migraine pathophysiology. Brain 2001;124:2490-2502.
80. Tassorelli C, Joseph SA. NADPH-diaphorase activity and Fos expression in brain nuclei following nitroglycerin administration. Brain Res 1995;695:37-44.
81. Nozaki K, Moskowitz MA, Boccalini P. CP-93,129, sumatriptan, dihydroergotamine block c-fos expression within rat trigeminal nucleus caudalis caused by chemical stimulation of the meninges. Br J Pharmacol 1992;106:409-415.
82. Hoskin KL, Bulmer DC, Goadsby PJ. c-fos expression in the trigeminocervical complex of the cat after stimulation of the superior sagittal sinus is reduced by L-NAME. Neurosci Lett 1999;266:173-176.
83. Knyihar-Csillik E, Vecsei L. Effect of a nitric oxide donor on nitroxergic nerve fibers in the rat dura mater. Neurosci Lett 1999;260:97-100.
84. Wei EP, Moskowitz MA, Boccalini P, Kontos HA. Calcitonin gene-related peptide mediates nitroglycerin and sodium nitroprusside-induced vasodilation in feline cerebral arterioles. Circ Res 1992;70:1313-1319.
85. Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 1993;33:48-56.
86. Goadsby PJ, Edvinsson L, Ekman R. Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Ann Neurol 1988;23:193-196.
87. Dimitriadou V, Buzzi MG, Theoharides TC, Moskowitz MA. Ultrastructural evidence for neurogenically mediated changes in blood vessels of the rat dura mater and tongue following antidromic trigeminal stimulation. Neuroscience 1992;48:187-203.
88. Moskowitz MA, Macfarlane R. Neurovascular and molecular mechanisms in migraine headaches. Cerebrovasc Brain Metab Rev 1993;5:159-177.
89. Doggrell SA. Migraine and beyond: cardiovascular therapeutic potential for CGRP modulators. Expert Opin Invest Drugs 2001;10:1131-1138.
90. Chen Z, Zhang J, Stamler JS. Identification of the enzymatic mechanism of nitroglycerin bioactivation. Proc Natl Acad Sci USA 2002;99:8306-8311.
91. Schroder H. Cytochrome P-450 mediates bioactivation of organic nitrates. J Pharmacol Exp Ther 1992;262:298-302.
92. Matsuzaki T, Sakanashi M, Nakasone J, et al. Effects of glutathione S-transferase inhibitors on nitroglycerin action in pig isolated coronary arteries. Clin Exp Pharmacol Physiol 2002;29:1091-1095.
93. Doroshow JH. Glutathione peroxidase and oxidative stress. Toxicol Lett 1995;82-83:395-398.
94. Bradley JR, Johnson DR, Pober JS. Endothelial activation by hydrogen peroxide: selective increases of intercellular adhesion molecule-1 and major histocompatibility complex class I. Am J Pathol 1993;142:1598-1609.
95. 3, is regulated by redox changes. Gene 1999;240:165-173.
96. Andrews GK. Regulation of metallothionein gene expression by oxidative stress and metal ions. Biochem Pharmacol 2000;59:95-104.
97. Ebadi M, Leuschen MP, el Refaey H, Hamada FM, Rojas P. The antioxidant properties of zinc and metallothionein. Neurochem Int 1996;29:159-166.
98. Franco AA, Odom RS, Rando TA. Regulation of antioxidant enzyme gene expression in response to oxidative stress and during differentiation of mouse skeletal muscle. Free Radic Biol Med 1999;27:1122-1132.
99. Flohé L, Brigelius-Flohe R, Saliou C, Traber MG, Packer L. Redox regulation of NF-kappaB activation. Free Radic Biol Med 1997;22:1115-1126.
100. Renard P, Zachary MD, Bougelet C, et al. Effects of antioxidant enzyme modulations on interleukin-1-induced nuclear factor kappa B activation. Biochem Pharmacol 1997;53:149-160.
101. Schoonbroodt S, Piette J. Oxidative stress interference with the nuclear factor-kappa B activation pathways. Biochem Pharmacol 2000;60:1075-1083.
102. Reuter U, Chiarugi A, Bolay H, Moskowitz MA. Nuclear factor-κB as a molecular target for migraine therapy. Ann Neurol 2002;51:507-516.
103. Baldwin AS Jr. The NF-kappaB and I kappaB proteins: new discoveries and insights. Annu Rev Immunol. 1996;14:649-683.
104. Bowie A, O'Neill LA. The interleukin-1 receptor/Toll-like receptor superfamily: signal generators for pro-inflammatory interleukins and microbial products. J Leukocyte Biol 2000;67:508-514.
105. Groenewegen WA, Knight DW, Heptinstall S. Compounds extracted from feverfew that have anti-secretory activity contain an alpha-methylene butyrolactone unit. J Pharm Pharmacol 1986;38:709-712.
106. Murphy JJ, Heptinstall S, Mitchell JR. Randomised double blind placebo-controlled trial of feverfew in migraine prevention. Lancet 1988;2:1891-1892.
107. De Weerdt CJ, Bootsma HPR, Hendricks H. Herbal medicines in migraine prevention: randomised double-blind, placebo controlled crossover trial of a feverfew preparation. Phytomedicine 1996;3:25-30.
108. Palevitch D, Earon G, Carasso R. Feverfew as a prophylactic treatment for migraine: a double blind placebo controlled study. Phytother Res 1997;11:506-511.
109. Pfaffenrath V, Diener HC, Fischer M, Friede M, Henneicke-von Zepelin HH. The efficacy and safety of Tanacetum parthenium (feverfew) in migraine prophylaxis: a double-blind, multicentre, randomized placebo-controlled dose-response study. Cephalalgia 2002;22:523-532.
110. Keinänen R, Vartiainen N, Koistinaho J. Molecular cloning and characterization of the rat inducible nitric oxide synthase (iNOS) gene. Gene 1999;234:297-305.
111. Xie QW, Kashiwabara Y, Nathan C. Role of transcription factor NF-kappa B/Rel in induction of nitric oxide synthase. J Biol Chem 1994;269:4705-4708.
112. Beck KF, Sterzel RB. Cloning and sequencing of the proximal promoter of the rat iNOS gene: activation of NFkappaB is not sufficient for transcription of the iNOS gene in rat mesangial cells. FEBS Lett 1996;394:263-267.
113. Spitsin SV, Farber JL, Bertovich M, Moehren G, Koprowski H, Michaels FH. Human- and mouse-inducible nitric oxide synthase promoters require activation of phosphatidylcholine-specific phospholipase C and NF-kappa B. Mol Med 1997;3:315-326.
114. Bogdan C, Rollinghoff M, Diefenbach A. The role of nitric oxide in innate immunity. Immunol Rev 2000;173:17-26.
115. Aurora SK, Ahmad BK, Welch KM, Bhardhwaj P, Ramadan NM. Transcranial magnetic stimulation confirms hyperexcitability of occipital cortex in migraine. Neurology 1998;50:1111-1114.
116. Battelli L, Black KR, Wray SH. Transcranial magnetic stimulation of visual area V5 in migraine. Neurology 2002;58:1066-1069.
117. Somjen GG. Mechanisms of spreading depression and hypoxic spreading depression-like depolarization. Physiol Rev 2001;81:1065-1096.
118. Tower DB, Young OM. The activities of butyrylcholinesterase and carbonic anhydrase, the rate of anaerobic glycolysis, and the question of a constant density of glial cells in cerebral cortices of various mammalian species from mouse to whale. J Neurochem 1973;20:269-278.
119. Sramka M, Brozek G, Bures J, Nadvornik P. Functional ablation by spreading depression: possible use in human stereotactic neurosurgery. Appl Neurophysiol 1977;40:48-61.
120. Mayevsky A, Doron A, Manor T, Meilin S, Zarchin N, Ouaknine GE. Cortical spreading depression recorded from the human brain using a multiparametric monitoring system. Brain Res 1996;740:268-274.
121. Strong AJ, Fabricius M, Boutelle MG, et al. Spreading and synchronous depressions of cortical activity in acutely injured human brain. Stroke 2002;33:2738-2743.
122. Bailey, P, von Bonin, G. The isocortex of man. Chicago: University of Illinois Press, 1951.
123. Lauritzen M. On the possible relation of spreading cortical depression to classical migraine. Cephalalgia 1985;5(suppl 2):47-51.
124. Ingvardsen BK, Laursen H, Olsen UB, Hansen AJ. Possible mechanism of c-fos expression in trigeminal nucleus caudalis following cortical spreading depression. Pain 1997;72:407-415.
125. Goadsby PJ. Migraine, aura, and cortical spreading depression: why are we still talking about it? Ann Neurol 2001;49:4-6.
126. Ebersberger A, Schaible HG, Averbeck B, Richter F. Is there a correlation between spreading depression, neurogenic inflammation, and nociception that might cause migraine headache? Ann Neurol 2001;49:7-13.
127. Hadjikhani N, Sanchez Del Rio M, et al. Mechanisms of migraine aura revealed by functional MRI in human visual cortex. Proc Natl Acad Sci USA 2001;98:4687-4692.
128. Arthurs OJ, Boniface S. How well do we understand the neural origins of the fMRI BOLD signal? Trends Neurosci 2002;25:27-31.
129. Cao Y, Welch KM, Aurora S, Vikingstad EM. Functional MRI-BOLD of visually triggered headache in patients with migraine. Arch Neurol 1999;56:548-554.
130. Moskowitz MA, Nozaki K, Kraig RP. Neocortical spreading depression provokes the expression of c-fos protein-like immunoreactivity within trigeminal nucleus caudalis via trigeminovascular mechanisms. J Neurosci 1993;13:1167-1177.
131. Bolay H, Reuter U, Dunn AK, Huang Z, Boas DA, Moskowitz MA. Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. Nature Med 2002;8:136-142.
132. Kemp JA, Leeson PD. The glycine site of the NMDA receptor: five years on. Trends Pharmacol Sci 1993;14:20-25.
133. Chen J, Graham SH, Moroni F, Simon RP. A study of the dose dependency of a glycine receptor antagonist in focal ischemia. J Pharmacol Exp Ther 1993;267:937-941.
134. Warner DS, Martin H, Ludwig P, McAllister A, Keana JFW, Weber E. In vivo models of cerebral ischemia: effects of parenterally administered NMDA receptor glycine site antagonists. J Cerebr Blood Flow Metab 1995;15:188-196.
135. Gill R, Hargreaves RJ, Kemp JA. The neuroprotective effect of the glycine site antagonist 3R-(1)-cis-4-methyl-HA966 (L-687,414) in a rat model of focal ischaemia. J Cerebr Blood Flow Metab 1995;15:197-204.
136. Tatlisumak T, Takano K, Meiler MR, Fisher M. A glycine site antagonist ZD9379 reduces number of spreading depressions and infarct size in rats with permanent middle cerebral artery occlusion. Acta Neurochir Suppl 2000;76:331-333.
137. Martin H, Warner DS, Todd MM. Effects of glycine receptor antagonism on spreading depression in the rat. Neurosci Lett 1994;180:285-289.
138. Obrenovitch TP, Zilkha E. Inhibition of cortical spreading depression by L-701,324, a novel antagonist at the glycine site of the N-methyl-D-aspartate receptor complex. Br J Pharmacol 1996;117:931-937.
139. Jing J, Aitken PG, Somjen GG. Role of calcium channels in spreading depression in rat hippocampal slices. Brain Res 1993;604:251-259.
140. Richter F, Ebersberger A, Schaible HG. Blockade of voltage-gated calcium channels in rat inhibits repetitive cortical spreading depression. Neurosci Lett 2002;334:123-126.
141. Ayata C, Shimizu-Sasamata M, Lo EH, Noebels JL, Moskowitz MA. Impaired neurotransmitter release and elevated threshold for cortical spreading depression in mice with mutations in the alpha1A subunit of P/Q type calcium channels. Neuroscience 2000;95:639-645.
142. Westenbroek RE, Sakurai T, Elliott EM, et al. Immunochemical identification and subcellular distribution of the alpha 1A subunits of brain calcium channels. J Neurosci 1995;15:6403-6418.
143. 2+ channels in mammallan central neurons. Trends Neurosci 1995;18:89-98.
144. 2+ channel gene CACNL1A4. Cell. 1996;87:543-552.
145. V2.1 current density in neurons. Proc Natl Acad Sci USA 2002;99:13284-13289.
146. tg) mouse thalami. J Neurophysiol 1995;81:2066-2074.
147. Kaube H, Herzog J, Kaufer T, Dichgans M, Diener HC. Aura in some patients with familial hemiplegic migraine can be stopped by intranasal ketamine. Neurology 2000;55:139-141.
148. Terwindt GM, Ophoff RA, van Eijk R, et al. Involvement of the CACNA1A gene containing region on 19p13 in migraine with and without aura. Neurology 2001;56:1028-1032.
149. McLeod RL, Aslanian R, del Prado M, et al. Sch 50971, an orally active histamine H3 receptor agonist, inhibits central neurogenic vascular inflammation and produces sedation in the guinea pig. J Pharmacol Exp Ther 1998;287:43-50.
150. A receptor-mediated effects of sodium valproate on dural plasma protein extravasation to substance P and trigeminal stimulation. Br J Pharmacol 1995;116:1661-1667.
151. Mitsikostas DD, Sanchez del Rio M, Waeber C, Moskowitz MA, Cutrer FM. The NMDA receptor antagonist MK-801 reduces capsaicin-induced c-fos expression within rat trigeminal nucleus caudalis. Pain 1998;76:239-248.
152. Mitsikostas DD, Sanchez del Rio M, Waeber C, Huang Z, Cutrer FM, Moskowitz MA. Non-NMDA glutamate receptors modulate capsaicin induced c-fos expression within trigeminal nucleus caudalis. Br J Pharmacol 1999;127:623-630.
153. Sernagor E, Kuhn D, Vyklicky L Jr, Mayer ML. Open channel block of NMDA receptor responses evoked by tricyclic antidepressants. Neuron 1989;2:1221-1227.
154. Gardner K. The genetic basis of migraine: how much do we know? Can J Neurol Sci 1999;26(suppl 3):S37-43.
155. Burns K, Clatworthy J, Martin L, et al. Tollip, a new component of the IL-1RI pathway, links IRAK to the IL-1 receptor. Nature Cell Biol 2000;2:346-351.
156. Jander S, Schroeter M, Peters O, Witte OW, Stoll G. Cortical spreading depression induces proinflammatory cytokine gene expression in the rat brain. J Cerebr Blood Flow Metab 2001;21:218-225.
157. Vyskocil F, Kritz N, Bures J. Potassium-selective microelectrodes used for measuring the extracellular brain potassium during spreading depression and anoxic depolarization in rats. Brain Res 1972;39:255-259.
158. Read SJ, Smith MI, Hunter AJ, Parsons AA. The dynamics of nitric oxide release measured directly and in real time following repeated waves of cortical spreading depression in the anaesthetised cat. Neurosci Lett 1997;232:127-130.
159. Allen GV, Barbrick B, Esser MJ. Trigeminal-parabrachial connections: possible pathway for nociception-induced cardiovascular reflex responses. Brain Res 1996;715:125-135.
160. Spencer SE, Sawyer WB, Wada H, Platt KB, Loewy AD. CNS projections to the pterygopalatine parasympathetic preganglionic neurons in the rat: a retrograde transneuronal viral cell body labeling study. Brain Res 1990;534:149-169.